These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice. Jurczak MJ; Saini S; Ioja S; Costa DK; Udeh N; Zhao X; Whaley JM; Kibbey RG Islets; 2018; 10(5):181-189. PubMed ID: 30118626 [TBL] [Abstract][Full Text] [Related]
3. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models. Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats. Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746 [TBL] [Abstract][Full Text] [Related]
5. Global deletion of G protein-coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β-cell turnover. Liu B; Ruz-Maldonado I; Persaud SJ Diabetes Obes Metab; 2024 Oct; 26(10):4591-4601. PubMed ID: 39113250 [TBL] [Abstract][Full Text] [Related]
6. Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans. Bensellam M; Shi YC; Chan JY; Laybutt DR; Chae H; Abou-Samra M; Pappas EG; Thomas HE; Gilon P; Jonas JC Diabetologia; 2019 Dec; 62(12):2273-2286. PubMed ID: 31624901 [TBL] [Abstract][Full Text] [Related]
7. Absence of Hung YH; Kim Y; Mitchell SB; Thorn TL; Aydemir TB Am J Physiol Endocrinol Metab; 2024 Jan; 326(1):E92-E105. PubMed ID: 38019082 [TBL] [Abstract][Full Text] [Related]
8. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668 [TBL] [Abstract][Full Text] [Related]
9. TLR4 is required for the obesity-induced pancreatic beta cell dysfunction. Li J; Chen L; Zhang Y; Zhang WJ; Xu W; Qin Y; Xu J; Zou D Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):1030-8. PubMed ID: 23985305 [TBL] [Abstract][Full Text] [Related]
10. Loss of function of renal Glut2 reverses hyperglycaemia and normalises body weight in mouse models of diabetes and obesity. de Souza Cordeiro LM; Bainbridge L; Devisetty N; McDougal DH; Peters DJM; Chhabra KH Diabetologia; 2022 Jun; 65(6):1032-1047. PubMed ID: 35290476 [TBL] [Abstract][Full Text] [Related]
11. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806 [TBL] [Abstract][Full Text] [Related]
12. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice. Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796 [TBL] [Abstract][Full Text] [Related]
13. PI3Kγ ablation does not promote diabetes in Breasson L; Sardi C; Becattini B; Zani F; Solinas G FASEB J; 2018 Jan; 32(1):319-329. PubMed ID: 28904022 [TBL] [Abstract][Full Text] [Related]
15. Deletion of Carboxypeptidase E in β-Cells Disrupts Proinsulin Processing but Does Not Lead to Spontaneous Development of Diabetes in Mice. Chen YC; Taylor AJ; Fulcher JM; Swensen AC; Dai XQ; Komba M; Wrightson KLC; Fok K; Patterson AE; Klein Geltink RI; MacDonald PE; Qian WJ; Verchere CB Diabetes; 2023 Sep; 72(9):1277-1288. PubMed ID: 37364047 [TBL] [Abstract][Full Text] [Related]
16. Deletion of ABCB10 in beta-cells protects from high-fat diet induced insulin resistance. Shum M; Segawa M; Gharakhanian R; Viñuela A; Wortham M; Baghdasarian S; Wolf DM; Sereda SB; Nocito L; Stiles L; Zhou Z; Gutierrez V; Sander M; Shirihai OS; Liesa M Mol Metab; 2022 Jan; 55():101403. PubMed ID: 34823065 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Signaling Pathways Associated with Pancreatic β-cell Adaptive Flexibility in Compensation of Obesity-linked Diabetes in Kang T; Boland BB; Jensen P; Alarcon C; Nawrocki A; Grimsby JS; Rhodes CJ; Larsen MR Mol Cell Proteomics; 2020 Jun; 19(6):971-993. PubMed ID: 32265294 [TBL] [Abstract][Full Text] [Related]
18. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Vallon V; Thomson SC Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313 [TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption. Li S; Wang N; Guo X; Li J; Zhang T; Ren G; Li D Biomed Pharmacother; 2018 Dec; 108():355-366. PubMed ID: 30227329 [TBL] [Abstract][Full Text] [Related]
20. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Kebede M; Alquier T; Latour MG; Semache M; Tremblay C; Poitout V Diabetes; 2008 Sep; 57(9):2432-7. PubMed ID: 18559658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]